AstraZeneca has acquired Omniose, a preclinical vaccine company in St. Louis, Missouri, Omniose announced on 10 November 2026. Omniose becomes a wholly owned subsidiary inside AstraZeneca's Infectious Disease Unit, bringing a platform that makes conjugate vaccines against bacterial infections in a single engineered E. coli cell. Financial terms were not disclosed.
The purchase ends a partnership that started in January 2024, when AstraZeneca took exclusive rights to the Omniose technology for up to three years. The target is bacteria that cause serious infections, including strains that resist antibiotics.
- Deal: AstraZeneca acquires Omniose outright; announced 10 November 2026 via Business Wire.
- Price: not disclosed.
- Structure: Omniose becomes a wholly owned subsidiary in AstraZeneca's Infectious Disease Unit.
- Technology: one engineered E. coli cell produces the sugar antigen, the carrier protein and the enzyme that joins them.
- Company: founded in 2016, nearly 25 staff, mostly scientists; about $14.5 million raised, mainly from NIH grants (St. Louis Magazine).
- Stage: all programmes are preclinical. No human data have been published.
What does Omniose bring to AstraZeneca?
Conjugate vaccines attach a bacterial surface sugar (a polysaccharide) to a carrier protein, which helps the immune system respond strongly to the sugar. Most are made by chemical conjugation, a multi-step process. Omniose engineers E. coli to produce the polysaccharide, an engineered carrier protein and a conjugating enzyme inside one cell, so the joining happens biologically.
In its 2024 collaboration release, Omniose said the enzyme-based method streamlines manufacturing compared with chemical conjugation. BioPharm International notes that the acquisition announcement gave no yield, purity or cost data to show that advantage.
Benjamin Moutier, Senior Vice President, Infectious Disease at AstraZeneca, said the platform "represents a differentiated approach to engineering conjugate vaccines", according to the release as reported by BioPharm International.
How did the deal come about?
On 5 January 2024, Omniose announced an exclusive collaboration giving AstraZeneca rights to its bioconjugation platform for up to three years. The work was to research vaccines for bacterial pathogens in AstraZeneca's early Vaccines and Immune Therapies pipeline, including multidrug-resistant bacteria. That exclusivity would have run to January 2027 at the latest. Mark Esser, then Vice President, Early R&D Vaccines and Immune Therapies at AstraZeneca, said in that release that "the development of alternative preventative interventions is critical".
| Date | Event |
|---|---|
| 2016 | Omniose founded by Mario Feldman, Christian Harding and Christine Szymanski |
| 2017 | Arch Grants award, St. Louis |
| April 2022 | Timothy Cooke appointed chief executive |
| October 2022 | NIH grant of $3.6 million for a Klebsiella pneumoniae vaccine |
| September 2023 | NIH grant of up to $3.0 million for a Group B Streptococcus vaccine |
| 5 January 2024 | Exclusive research collaboration with AstraZeneca |
| 10 November 2026 | Acquisition by AstraZeneca announced |
Who is Omniose?
St. Louis Magazine reports that Omniose works from BioGenerator's laboratories in the Cortex Innovation District in St. Louis and has nearly 25 employees, most of them scientists. It raised about $14.5 million, mostly non-dilutive NIH grants, and had no venture capital funding. BioGenerator holds equity. The pipeline covers Klebsiella, Pseudomonas and Group B Streptococcus, plus two undisclosed programmes with AstraZeneca.
Timothy Cooke, who led Omniose as chief executive, told the magazine: "The acquisition by AstraZeneca is a great outcome for both organizations." Jim McCarter of BioGenerator said he hoped AstraZeneca would keep a St. Louis footprint, which the company has not confirmed.
| Item | Status |
|---|---|
| Purchase price | Not disclosed |
| Milestone or earn-out payments | Not disclosed |
| Target pathogens of the AstraZeneca programmes | Not disclosed |
| Clinical trial timelines | Not disclosed |
| Future of the St. Louis site and staff | Not confirmed |
Why does AstraZeneca want bacterial vaccines?
Both the 2024 collaboration and the 2026 acquisition announcement name serious bacterial infections, including those complicated by antimicrobial resistance, as the target. Cooke told St. Louis Magazine that the pathogens Omniose works on kill a combined 2.7 million people a year; that is his estimate and the magazine gave no separate source. Omniose's NIH grants funded work on vaccines against Klebsiella pneumoniae and Group B Streptococcus.
Is there an Irish angle?
The deal itself has no announced Irish element: Omniose is a US company and its programmes are preclinical. AstraZeneca is a major employer in Ireland through Alexion, AstraZeneca Rare Disease. Alexion says it employs over 1,300 people across two manufacturing facilities in Dublin and Athlone, runs its global supply chain from Ireland and hosts several global teams here. Priya Life Science tracks the group on its AstraZeneca and Alexion, AstraZeneca Rare Disease company pages, and AstraZeneca-sponsored studies on the AstraZeneca trials page.
Frequently asked questions
How much did AstraZeneca pay for Omniose?
The price was not disclosed by either company.
What is bioconjugation?
It is a way of making conjugate vaccines in which a living cell, here engineered E. coli, builds the sugar antigen and carrier protein and joins them with an enzyme, instead of joining them chemically.
Are any Omniose vaccines in human trials?
No. The programmes are preclinical and no clinical safety or immune response data have been published.
Will Omniose keep operating in St. Louis?
That has not been confirmed. Omniose now operates as a subsidiary within AstraZeneca's Infectious Disease Unit.
Outlook
The next milestone to watch is a first clinical trial of a vaccine built on the Omniose platform, and whether AstraZeneca names its target pathogens. Priya Life Science will update this report if AstraZeneca publishes further detail.
Sources
- Omniose via Business Wire, Omniose Announces Its Acquisition by AstraZeneca, 10 November 2026
- BioPharm International, AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform, 10 November 2026
- BioBuzz, Omniose Announces Its Acquisition by AstraZeneca, 11 November 2026
- St. Louis Magazine, AstraZeneca acquires St. Louis-based vaccine startup Omniose, 11 November 2026
- Omniose, Omniose announces scientific collaboration with AstraZeneca to research vaccines for serious bacterial diseases, 5 January 2024
- Omniose, News: NIH grant awards (October 2022, September 2023) and leadership appointments (April 2022)
- Alexion, AstraZeneca Rare Disease, Alexion in Ireland
Cover image: the AstraZeneca Discovery Centre on the Cambridge Biomedical Campus, UK. It is not an Omniose site. Photo: Mr Ignavy, geograph.org.uk, CC BY-SA 2.0, via Wikimedia Commons and geograph.org.uk, cropped.